Treatment Convenience in Patients Treated With Dabigatran for Stroke Prophylaxis in Atrial Fibrillation (SPAF)

Boehringer Ingelheim

Status

Completed

Conditions

Atrial Fibrillation

Study type

Observational

Funder types

Industry

Identifiers

NCT02839746

1160.253

Details and patient eligibility

About

Describe patient and physician assessed factors for patient well-being when treated with Pradaxa for stroke and embolism prevention in atrial fibrillation either compared to previous antithrombotic treatment (switcher)

Enrollment

671 patients

Sex

All

Ages

18 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Written informed consent prior to participation
Female and male patients 18 years of age or older with a diagnosis of non-valvular atrial fibrillation.
At least 6 months of continuous vitamin K antagonist (VKA) treatment for stroke prevention prior to baseline assessment.
Patients switched to Pradaxa® according to Summary of Product Characteristics, therapeutic positioning report from Spanish competent authorities and visa from each autonomous community.

Exclusion criteria

Contraindication to the use of Pradaxa® or VKA as described in the Summary of Product Characteristics (SmPC)
Patients receiving Pradaxa® or VKA for any other condition than stroke prevention in non-valvular atrial fibrillation.
Current participation in any clinical trial of a drug or device